About this trial
To assess the discriminative properties of pleural fluid (PF) N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure (HF)-associated pleural effusions (PE).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients hospitalized for heart failure and pleural effusion
Pleural tapping indicated for pleural fluid analysis.
Aged 18 years old or above
Disqualifiers
History of intrapleural therapy (including talc and fibrinolytic) in the ipsilateral pleural space.
History of surgical decortication or pleurodesis in the ipsilateral pleural space.
Ipsilateral thoracic or cardiac surgery in the past 3 months.
Failure to obtain informed consent due to the patient's refusal or cognitive impairment.
Trial population
Patients who are admitted to the Department of Medicine \& Therapeutics, Prince of Wales Hospital (PWH) who fulfil the inclusion and exclusion criteria
Trial design
Case-control
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Comparison of the diagnostic performance of PF NTproBNP level in the diagnosis of HF-associated pleural effusions with other conventional biochemical criteria
Pleural fluid NTproBNP will be measured in patients with pleural effusion of various aetiologies including malignancy, pleural infection, heart failure and other causes of volume overload. The sensitivity and specificity of an elevated pleural fluid NTproBNP level in successfully identifying a pleural effusion due to underlying heart failure will be measured and compared against existing classification criteria for pleural effusion such as Light's Criteria, pleural-serum protein gradient or albumin gradient.
Secondary outcomes
To measure the PF NTproBNP level in patients with pleural effusion of various aetiologies
Correlation of clinical factors that may affect the levels of pleural fluid NTproBNP such as echocardiographic features, presence of comorbidities, nutritional status, serum albumin level, levels of inflammatory markers and presence of infection
Clinical data of patients admitted to the hospital with pleural effusion will be measured and recorded. Statistical analysis will then be performed to evaluate for degree of correlation between the presence or severity of a clinical parameter, echocardiogram results e.g. severe valvular stenosis, or, e.g. presence of medical comorbidities or presence of concomitant infection, and the levels of NTproBNP identified in the patient's pleural fluid detected within same admission.
To correlate the PF NTproBNP levels with the echocardiographic features and prognosis of patients with heart failure
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Chinese University of Hong Kong
Lead sponsor
Roche Diagnostics GmbH
Collaborator